Teva launches Olanzapine and Fluoxetine Capsules for treatment of depression

Download PDF Copy

Jun 22 2012

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of Olanzapine and Fluoxetine Capsules USP 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, and 12 mg/50 mg, the Company's generic equivalent of Symbyax®.

Symbyax® is marketed by Lilly USA and approved for the acute treatment of treatment-resistant depression and bipolar I depression in adults. The brand product had annual sales of approximately $82 million in the United States, based on IMS sales data.

Source: Teva Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Research sheds new light on depression’s biological roots

Artificial intelligence detects mild depression through micro-movements in facial muscles

Keto diet reduces depression symptoms by 70% in college students

Association between depression and diabetes remains the same, regardless of where people live

How shifting mindsets after catastrophes can promote mental and physical health

Australian teachers face severe stress and unmanageable workloads at alarming rates

Personalized form of electric brain stimulation shows promise for treating depression

New molecular mechanism offers hope for treating depression in the elderly

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.